Burzynski: FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston CLINICAL TRIALS

” … in 1997, his medical practice was expanded to include traditional cancer treatment options such as

chemotherapy,

gene targeted therapy,

immunotherapy and

hormonal therapy

in response to FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s

Antineoplaston CLINICAL TRIALS
http://www.sec.gov/Archives/edgar/data/724445/000091205702038660/a2091272z10qsb.txt

Advertisement